Skinvisible's Patent Pending Hand Sanitizer Approval Extended for Ten Years
16 Mayo 2014 - 1:51PM
Marketwired
Skinvisible's Patent Pending Hand Sanitizer Approval Extended for
Ten Years
Skinvisible Prepares to Obtain Authorization for DermSafe(R)
Through-Out Europe
LAS VEGAS, NV--(Marketwired - May 16, 2014) - Skinvisible
Pharmaceuticals, Inc. (OTCBB: SKVI) (OTCQB: SKVI) has received
notification from the Federal Public Service (FPS) Health, Food
Chain Safety and Environment in Belgium that it has extended the
registration of DermSafe, its unique antimicrobial hand sanitizer,
for an additional ten years; until December 31, 2024. This
replaces the previous authorization which was granted for only two
years. DermSafe is regulated in accordance with Biocidal
Product Regulation (EU) No. 528/2012. BPR regulates the marketing
and use of biocidal products and has put into place regulations to
improve the use and safety of biocidal products marketed by member
states in the European Union.
DermSafe's approval in Belgium will act as the "Reference Member
State" which will be leveraged for further authorization
through-out Europe. This is a straight-forward process which
involves notification in most countries. The entire EU
authorization process is expected to be completed within five
months.
"This extended authorization by the FPS in Belgium has provided
Skinvisible with the opportunity to market DermSafe in Europe over
a much greater period of time than previously granted," stated Mr.
Terry Howlett, President and CEO. "We believe DermSafe is a product
that can help prevent the spread of debilitating and fatal germs in
hospitals, at home, at work and in the military and we are eager to
make it available through-out Europe through distributors and
licensees."
DermSafe is a non-alcohol hand sanitizer made with 4%
chlorhexidine gluconate which has demonstrated persistent
protection of both gram-negative and gram-positive bacteria and
viruses through independent laboratory studies. Successful
studies were performed against Methicillin-resistant Staphylococcus
aureus (MRSA) and Escherichia coli (E. coli) as well as the
Influenza A viruses H5N1 and H1N9. Skinvisible is currently
investigating further testing of DermSafe against the Middle East
Respiratory Syndrome Coronavirus (MERS-CoV); a SARS-like virus and
a new avian influenza A virus called H7N9.
DermSafe is currently available from Alto Pharmaceuticals in
Canada. Skinvisible is seeking additional licensees in select
territories for commercial and/or retail markets.
About Skinvisible
Pharmaceuticals, Inc Skinvisible Pharmaceuticals is a
research-and-development company that licenses its proprietary
formulations made with Invisicare, its patented polymer delivery
system that offers life-cycle management and unique enhancements
for topically delivered products. Invisicare holds active
ingredients on the skin for extended periods of time resisting both
wash off and perspiration along with controlling the release of
actives and reducing irritation. Skinvisible receives a combination
of research and development fees, upfront license fees, and ongoing
royalties for the life of the Invisicare patent. Skinvisible's
value also lies in its ability to continually generate new IP on
topical products formulated with
Invisicare. www.skinvisible.com and www.invisicare.com.
Forward-Looking
Statements: This press release contains
'forward looking' statements within the meaning of Section 21A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks
and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending March 31, 2014).
Corporate Contact: Doreen McMorran Skinvisible Pharmaceuticals,
Inc. Phone: 702-433-7154 Email: info@skinvisible.com
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
